Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Mead Johnson

This article was originally published in The Tan Sheet

Executive Summary

Mead Johnson: Submits citizen petition asking FDA to remove chloride from the list of nutrients with Reference Daily Intakes (RDIs) and instead establish a chloride Daily Reference Value (DRV). Maintaining an RDI for chloride "but DRVs for the other electrolytes (sodium and potassium) will create a label problem" for meal replacement products and medical foods that provide all three, the company argues. Mead Johnson used labeling from its Sustacal liquid nutrition for institutional use and Isocal liquid tube feeding formula to illustrate the point. FDA set an RDI of 3,400 mg for chloride in December ("The Tan Sheet" Jan. 1, p. 22)...

Mead Johnson: Submits citizen petition asking FDA to remove chloride from the list of nutrients with Reference Daily Intakes (RDIs) and instead establish a chloride Daily Reference Value (DRV). Maintaining an RDI for chloride "but DRVs for the other electrolytes (sodium and potassium) will create a label problem" for meal replacement products and medical foods that provide all three, the company argues. Mead Johnson used labeling from its Sustacal liquid nutrition for institutional use and Isocal liquid tube feeding formula to illustrate the point. FDA set an RDI of 3,400 mg for chloride in December ("The Tan Sheet" Jan. 1, p. 22)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel